Sympathomimetic inefficiency in restoring contractility in the acute or chronic β-blocker-treated ischaemic heart

Comparison with a new agent

Giovan Giuseppe Mattera, Emilio Vanoli, Jean Pierre Gagnol, Francesca Maria Paola Loi, Franco Borsini, Paolo Carminati

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Adequate pharmacologic cardiac support in acute myocardial infarction (MI), as well as in chronic MI patients under β-blocker therapy, is problematic due to the impaired cardiac response to β-adrenergic agonists. New therapeutic approaches could resolve this problem. Istaroxime (ISTA) is a new Na+,K+-ATPase inhibitor and SERCA2 agonist. Aims: To evaluate: 1) the effects of dobutamine (DOB) on left ventricular function in early (48-72 h) and late (14 days) phases of a post-MI canine model, compared to ISTA, and 2) the efficacy of DOB in chronic left ventricular dysfunction (6 months post-MI) in dogs pre-treated or not with a β-blocker, compared with ISTA and milrinone (MIL). Results: When compared to the effects in healthy animals, DOB increased contractility only slightly in the first 48-72 h post-MI, whereas its efficacy recovered partially by day 14 and fully by 6 months after MI. ISTA had a greater effect on contractility than DOB and improved relaxation, while DOB did not. Moreover, ß-adrenergic blockade inhibited the inotropic action of DOB, without altering the effect of ISTA. Surprisingly, ß-adrenergic blockade blunted the effects of MIL. Conclusion: ISTA may represent a novel strategy for enhancing left ventricular performance even in the context of acute MI and/or concomitant β-adrenergic blockade.

Original languageEnglish
Pages (from-to)990-996
Number of pages7
JournalEuropean Journal of Heart Failure
Volume10
Issue number10
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Sympathomimetics
Dobutamine
Myocardial Infarction
Adrenergic Agents
Milrinone
Adrenergic Agonists
Left Ventricular Dysfunction
Left Ventricular Function
Istaroxime
Canidae
Dogs
Therapeutics

Keywords

  • β-blockers
  • Acute myocardial infarction
  • Contractility
  • Dobutamine
  • Istaroxime
  • Milrinone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Sympathomimetic inefficiency in restoring contractility in the acute or chronic β-blocker-treated ischaemic heart : Comparison with a new agent. / Mattera, Giovan Giuseppe; Vanoli, Emilio; Gagnol, Jean Pierre; Loi, Francesca Maria Paola; Borsini, Franco; Carminati, Paolo.

In: European Journal of Heart Failure, Vol. 10, No. 10, 10.2008, p. 990-996.

Research output: Contribution to journalArticle

Mattera, Giovan Giuseppe ; Vanoli, Emilio ; Gagnol, Jean Pierre ; Loi, Francesca Maria Paola ; Borsini, Franco ; Carminati, Paolo. / Sympathomimetic inefficiency in restoring contractility in the acute or chronic β-blocker-treated ischaemic heart : Comparison with a new agent. In: European Journal of Heart Failure. 2008 ; Vol. 10, No. 10. pp. 990-996.
@article{aa8ca5046acf4454a9196e4b6e3ab20a,
title = "Sympathomimetic inefficiency in restoring contractility in the acute or chronic β-blocker-treated ischaemic heart: Comparison with a new agent",
abstract = "Background: Adequate pharmacologic cardiac support in acute myocardial infarction (MI), as well as in chronic MI patients under β-blocker therapy, is problematic due to the impaired cardiac response to β-adrenergic agonists. New therapeutic approaches could resolve this problem. Istaroxime (ISTA) is a new Na+,K+-ATPase inhibitor and SERCA2 agonist. Aims: To evaluate: 1) the effects of dobutamine (DOB) on left ventricular function in early (48-72 h) and late (14 days) phases of a post-MI canine model, compared to ISTA, and 2) the efficacy of DOB in chronic left ventricular dysfunction (6 months post-MI) in dogs pre-treated or not with a β-blocker, compared with ISTA and milrinone (MIL). Results: When compared to the effects in healthy animals, DOB increased contractility only slightly in the first 48-72 h post-MI, whereas its efficacy recovered partially by day 14 and fully by 6 months after MI. ISTA had a greater effect on contractility than DOB and improved relaxation, while DOB did not. Moreover, {\ss}-adrenergic blockade inhibited the inotropic action of DOB, without altering the effect of ISTA. Surprisingly, {\ss}-adrenergic blockade blunted the effects of MIL. Conclusion: ISTA may represent a novel strategy for enhancing left ventricular performance even in the context of acute MI and/or concomitant β-adrenergic blockade.",
keywords = "β-blockers, Acute myocardial infarction, Contractility, Dobutamine, Istaroxime, Milrinone",
author = "Mattera, {Giovan Giuseppe} and Emilio Vanoli and Gagnol, {Jean Pierre} and Loi, {Francesca Maria Paola} and Franco Borsini and Paolo Carminati",
year = "2008",
month = "10",
doi = "10.1016/j.ejheart.2008.07.007",
language = "English",
volume = "10",
pages = "990--996",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley & Sons, Ltd",
number = "10",

}

TY - JOUR

T1 - Sympathomimetic inefficiency in restoring contractility in the acute or chronic β-blocker-treated ischaemic heart

T2 - Comparison with a new agent

AU - Mattera, Giovan Giuseppe

AU - Vanoli, Emilio

AU - Gagnol, Jean Pierre

AU - Loi, Francesca Maria Paola

AU - Borsini, Franco

AU - Carminati, Paolo

PY - 2008/10

Y1 - 2008/10

N2 - Background: Adequate pharmacologic cardiac support in acute myocardial infarction (MI), as well as in chronic MI patients under β-blocker therapy, is problematic due to the impaired cardiac response to β-adrenergic agonists. New therapeutic approaches could resolve this problem. Istaroxime (ISTA) is a new Na+,K+-ATPase inhibitor and SERCA2 agonist. Aims: To evaluate: 1) the effects of dobutamine (DOB) on left ventricular function in early (48-72 h) and late (14 days) phases of a post-MI canine model, compared to ISTA, and 2) the efficacy of DOB in chronic left ventricular dysfunction (6 months post-MI) in dogs pre-treated or not with a β-blocker, compared with ISTA and milrinone (MIL). Results: When compared to the effects in healthy animals, DOB increased contractility only slightly in the first 48-72 h post-MI, whereas its efficacy recovered partially by day 14 and fully by 6 months after MI. ISTA had a greater effect on contractility than DOB and improved relaxation, while DOB did not. Moreover, ß-adrenergic blockade inhibited the inotropic action of DOB, without altering the effect of ISTA. Surprisingly, ß-adrenergic blockade blunted the effects of MIL. Conclusion: ISTA may represent a novel strategy for enhancing left ventricular performance even in the context of acute MI and/or concomitant β-adrenergic blockade.

AB - Background: Adequate pharmacologic cardiac support in acute myocardial infarction (MI), as well as in chronic MI patients under β-blocker therapy, is problematic due to the impaired cardiac response to β-adrenergic agonists. New therapeutic approaches could resolve this problem. Istaroxime (ISTA) is a new Na+,K+-ATPase inhibitor and SERCA2 agonist. Aims: To evaluate: 1) the effects of dobutamine (DOB) on left ventricular function in early (48-72 h) and late (14 days) phases of a post-MI canine model, compared to ISTA, and 2) the efficacy of DOB in chronic left ventricular dysfunction (6 months post-MI) in dogs pre-treated or not with a β-blocker, compared with ISTA and milrinone (MIL). Results: When compared to the effects in healthy animals, DOB increased contractility only slightly in the first 48-72 h post-MI, whereas its efficacy recovered partially by day 14 and fully by 6 months after MI. ISTA had a greater effect on contractility than DOB and improved relaxation, while DOB did not. Moreover, ß-adrenergic blockade inhibited the inotropic action of DOB, without altering the effect of ISTA. Surprisingly, ß-adrenergic blockade blunted the effects of MIL. Conclusion: ISTA may represent a novel strategy for enhancing left ventricular performance even in the context of acute MI and/or concomitant β-adrenergic blockade.

KW - β-blockers

KW - Acute myocardial infarction

KW - Contractility

KW - Dobutamine

KW - Istaroxime

KW - Milrinone

UR - http://www.scopus.com/inward/record.url?scp=53249109365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53249109365&partnerID=8YFLogxK

U2 - 10.1016/j.ejheart.2008.07.007

DO - 10.1016/j.ejheart.2008.07.007

M3 - Article

VL - 10

SP - 990

EP - 996

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 10

ER -